{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:35:08Z","timestamp":1762875308594},"reference-count":28,"publisher":"Wiley","issue":"s3","license":[{"start":{"date-parts":[[2010,4,23]],"date-time":"2010-04-23T00:00:00Z","timestamp":1271980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> For patients with haemophilia, the development of inhibitors complicates treatment, and inhibitor patients may thus have a range of unmet needs. Although successful inhibitor eradication will render patients responsive to factor replacement therapy, with potentially beneficial effects on long\u2010term outcomes, this may not always be possible. Physicians treating inhibitor patients should aim to achieve reliable control of bleeding episodes, and the prevention of joint disease should also be a priority. Patients with high\u2010titre inhibitors require therapy with bypassing agents \u2013 recombinant activated factor VII (rFVIIa) or a plasma\u2010derived activated prothrombin complex concentrate (pd\u2010APCC) \u2013 for the treatment of bleeding. When treating joint haemorrhage in inhibitor patients, both aggressive treatment of intercurrent joint bleeds and prophylaxis should be considered, although evidence is needed as to whether prophylaxis with bypassing agents can significantly delay\/prevent the development of osteochondral changes in patients with inhibitors. Despite physicians\u2019 best efforts, joint disease may ultimately occur in inhibitor patients, and in such instances optimizing treatment, of both early and late stages, is important. There is no single therapeutic modality for dealing with the various treatment challenges posed by inhibitor patients, but overall goals should be to improve quality of life, with the provision of cost\u2010effective care that aims to maintain physical function.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2010.02260.x","type":"journal-article","created":{"date-parts":[[2010,4,23]],"date-time":"2010-04-23T10:40:34Z","timestamp":1272019234000},"page":"46-51","source":"Crossref","is-referenced-by-count":13,"title":["Meeting unmet needs in inhibitor patients"],"prefix":"10.1111","volume":"16","author":[{"given":"V. S.","family":"BLANCHETTE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"MANCO\u2010JOHNSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,4,23]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00780.x"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.429"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2004.00710.x"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615621"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2000.02327.x"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615388"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00059.x"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH05-07-0510"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01772.x"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01601.x"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00925.x"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01497.x"},{"key":"e_1_2_9_14_2","first-page":"430","article-title":"Serum sickness following treatment with rituximab","volume":"34","author":"Todd DJ","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1548-5315(11)70270-4"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06490.x"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01732.x"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200004001-00010"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02647.x"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00546.x"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2337"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02663.x"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01915.x"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01953.x"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200210000-00007"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00383.x"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01447.x"},{"key":"e_1_2_9_29_2","unstructured":"National Hemophilia Foundation.MASAC Document # 176. MASAC recommendations following radionuclide synovectomy.2006. Available athttp:\/\/www.hemophilia.org\/NHFWeb\/MainPgs\/MainNHF.aspx?menuid=57&contentid=692Accessed October 19 2009."}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2010.02260.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2010.02260.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T16:58:53Z","timestamp":1694451533000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2010.02260.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,23]]},"references-count":28,"journal-issue":{"issue":"s3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1365-2516.2010.02260.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2010.02260.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,23]]}}}